Resources
These essential resources contain important information to minimise the risk of meningococcal infection associated with zilucoplan.
The patient or, if appropriate, their caregiver should be educated about treatment risks and provided with a Patient Alert Card. It is important for patients treated with zilucoplan to carry the Patient Alert Card with them at all times throughout treatment and for two months after their last dose.
Please refer to the Summary of Product Characteristics for more detailed safety information about zilucoplan.
You have selected Belgium (Dutch).
Change your desired country and language here
Dit informatiemateriaal kan worden geraadpleegd op de website van het FAGG: http://www.fagg.be > zoek informatie over een vergund geneesmiddel > Zilbrysq ingeven in het zoekveld > RMA aanklikken
